Univdatos Whatsapp
Anticoagulants Market

Global Anticoagulants Market is Expected to Foresee Significant Growth During the Forecast Period. North America to Witness the Highest Growth

Global anticoagulants market is expected to grow significantly by 2027 expanding at a reasonable CAGR of around 7% during the forecast period (2021-2027). Anticoagulants are also called blood thinners and are used for treating and preventing blood clots which can block blood vessels. This blockage can occur in a vein or artery and can lead to serious complications such as heart attack or stroke as the clot disrupts the flow of blood to important organs.

For a detailed analysis of the anticoagulants browse through – https://univdatos.com/report/anticoagulants-market/

The global anticoagulants market is anticipated to witness an uptick with the development of social society leading to changes in diet and other lifestyles. This along with the rapid increase in the number of cases of atrial fibrillation and heart attacks across the globe is driving the market. For instance, as per CDC, It is estimated that 12.1 million people in the United States will have atrial fibrillation by 2030. In 2019, atrial fibrillation accounted for 26,535 deaths. Also, in 2019, 17.9 million people died from cardiovascular diseases. Of these deaths, 85% were due to heart attack and stroke, as per the World Health Organization. Furthermore, increased awareness regarding cardiovascular health and the corresponding rise in new therapeutic launches are some of the other factors contributing to the anticoagulants market globally.

For a detailed analysis of the market drivers of anticoagulants browse through – https://univdatos.com/get-a-free-sample-form-php/?product_id=23775

Based on the drug class, the anticoagulants market is segmented into novel oral anticoagulants (NOACs), heparin & low molecular weight heparin (LMWH), vitamin K antagonist, and others. The novel oral anticoagulants segment accounted for a significant market share in 2020 and it is estimated that it will grow rapidly during the projected timeframe. The segment is anticipated to grow on account of the growing adoption of NOACs in developing countries and the high preference for these drugs over warfarin. Some of the common NOACs are dabigatran, and rivaroxaban, among others.

Based on application, the anticoagulants market is divided into pulmonary embolism, deep vein thrombosis, atrial fibrillation & heart attack, and others. The pulmonary embolism segment occupied the major share of the anticoagulants market in 2020 and it is expected to grow with a substantial CAGR in the upcoming years owing to the growing prevalence of this disease and the availability of the most commercially successful anticoagulant, Eliquis, for this condition. 

Request for Sample of the report browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=23775

Additionally, the report provides detailed report also provides insights into the global intraoperative neuromonitoring market according to the regions such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America dominated the market in 2020 owing to the well-established market players and increasing geriatric population.

Some of the major players operating in the market are Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Abbott Laboratories, Sanofi S.A., Pfizer, Inc., GlaxoSmithKline plc., Dr. Reddy’s Laboratories, etc. Several M&A’s along with partnerships have been undertaken by these players to develop anticoagulants.

Global Anticoagulants Market Segmentation

Market Insight, by Drug Class

  • Novel Oral Anticoagulants (NOACs)
  • Heparin and Low Molecular Weight Heparin (LMWH)
  • Vitamin K Antagonist
  • Others

Market Insight, by Application

  • Pulmonary Embolism
  • Deep Vein Thrombosis (DVT)
  • Atrial fibrillation & heart attack
  • Others

Market Insight, by Route of Administration

  • Pulmonary Embolism
  • Deep Vein Thrombosis (DVT)
  • Atrial fibrillation & heart attack
  • Others

Market Insight, by Region

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • United Kingdom
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Australia
    • Japan
    • Rest of Asia-Pacific
  • Rest of World

Top Company Profiles

  • Johnson & Johnson
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company
  • Abbott Laboratories
  • Sanofi S.A.
  • Pfizer, Inc.
  • GlaxoSmithKline plc.
  • Dr. Reddy’s Laboratories

Leave A Comment

Select Language